ACE2 and COVID-19: Our results demonstrate weaker humoral responses to COVID-19 mRNA vaccines in older versus younger adults, signified by reduced magnitude and durability of spike-specific binding antibodies, ACE2 competition activity, and neutralizing antibody activity even after correction for potential confounders.